Literature DB >> 35218143

Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults.

Chengjie Xiong1,2, Jingqin Luo1,3,4, Suzanne E Schindler2,5, Anne M Fagan2,5, Tammie Benzinger2,6, Jason Hassenstab2,5, Joyce E Balls-Berry2,5, Folasade Agboola1,2, Elizabeth Grant1,2, Krista L Moulder2,5, John C Morris2,5,7.   

Abstract

INTRODUCTION: Longitudinal changes in Alzheimer's disease (AD) biomarkers, including cerebrospinal fluid (CSF) analytes, amyloid uptakes from positron emission tomography (PET), structural outcomes from magnetic resonance imaging (MRI), and cognition, have not been compared between Blacks and Whites.
METHODS: A total of 179 Blacks and 1180 Whites who were cognitively normal at baseline and had longitudinal data from at least one biomarker modality were analyzed for the annual rates of change.
RESULTS: CSF amyloid beta (Aβ)42/Aβ40 declined more slowly (P = .0390), and amyloid (PET) accumulated more slowly (P = .0157), in Blacks than Whites. CSF Aβ42 changed in opposite directions over time between Blacks and Whites (P = .0039). The annual increase in CSF total tau and phosphorylated tau181 for Blacks was about half of that for Whites. DISCUSSION: Longitudinal racial differences in amyloid biomarkers are observed. It will be important to comprehensively and prospectively examine the effects of apolipoprotein E genotype and sociocultural factors on these differences.
© 2022 the Alzheimer's Association.

Entities:  

Keywords:  Alzheimer's disease; cerebrospinal fluid biomarkers; imaging biomarkers; longitudinal; racial difference

Year:  2022        PMID: 35218143      PMCID: PMC9402805          DOI: 10.1002/alz.12608

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   16.655


  34 in total

1.  Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.

Authors:  Joseph L Price; Daniel W McKeel; Virginia D Buckles; Catherine M Roe; Chengjie Xiong; Michael Grundman; Lawrence A Hansen; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Charles D Smith; Daron G Davis; Frederick A Schmitt; William R Markesbery; Jeffrey Kaye; Roger Kurlan; Christine Hulette; Brenda F Kurland; Roger Higdon; Walter Kukull; John C Morris
Journal:  Neurobiol Aging       Date:  2009-04-18       Impact factor: 4.673

2.  Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.

Authors:  Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan
Journal:  Lancet Neurol       Date:  2013-09-04       Impact factor: 44.182

3.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

4.  Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.

Authors:  John C Morris; Suzanne E Schindler; Lena M McCue; Krista L Moulder; Tammie L S Benzinger; Carlos Cruchaga; Anne M Fagan; Elizabeth Grant; Brian A Gordon; David M Holtzman; Chengjie Xiong
Journal:  JAMA Neurol       Date:  2019-03-01       Impact factor: 18.302

5.  The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.

Authors:  William E Klunk; Robert A Koeppe; Julie C Price; Tammie L Benzinger; Michael D Devous; William J Jagust; Keith A Johnson; Chester A Mathis; Davneet Minhas; Michael J Pontecorvo; Christopher C Rowe; Daniel M Skovronsky; Mark A Mintun
Journal:  Alzheimers Dement       Date:  2014-10-28       Impact factor: 21.566

6.  Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.

Authors:  Anne M Fagan; Chengjie Xiong; Mateusz S Jasielec; Randall J Bateman; Alison M Goate; Tammie L S Benzinger; Bernardino Ghetti; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Stephen Salloway; Peter R Schofield; Reisa A Sperling; Daniel Marcus; Nigel J Cairns; Virginia D Buckles; Jack H Ladenson; John C Morris; David M Holtzman
Journal:  Sci Transl Med       Date:  2014-03-05       Impact factor: 17.956

7.  Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies.

Authors:  Yi Su; Shaney Flores; Guoqiao Wang; Russ C Hornbeck; Benjamin Speidel; Nelly Joseph-Mathurin; Andrei G Vlassenko; Brian A Gordon; Robert A Koeppe; William E Klunk; Clifford R Jack; Martin R Farlow; Stephen Salloway; Barbara J Snider; Sarah B Berman; Erik D Roberson; Jared Brosch; Ivonne Jimenez-Velazques; Christopher H van Dyck; Douglas Galasko; Shauna H Yuan; Suman Jayadev; Lawrence S Honig; Serge Gauthier; Ging-Yuek R Hsiung; Mario Masellis; William S Brooks; Michael Fulham; Roger Clarnette; Colin L Masters; David Wallon; Didier Hannequin; Bruno Dubois; Jeremie Pariente; Raquel Sanchez-Valle; Catherine Mummery; John M Ringman; Michel Bottlaender; Gregory Klein; Smiljana Milosavljevic-Ristic; Eric McDade; Chengjie Xiong; John C Morris; Randall J Bateman; Tammie L S Benzinger
Journal:  Alzheimers Dement (Amst)       Date:  2019-02-22

8.  Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia.

Authors:  Chengjie Xiong; Jingqin Luo; Dean Coble; Folasade Agboola; Walter Kukull; John C Morris
Journal:  Alzheimers Dement       Date:  2020-02-17       Impact factor: 21.566

9.  Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies.

Authors:  Yi Su; Shaney Flores; Russ C Hornbeck; Benjamin Speidel; Andrei G Vlassenko; Brian A Gordon; Robert A Koeppe; William E Klunk; Chengjie Xiong; John C Morris; Tammie L S Benzinger
Journal:  Neuroimage Clin       Date:  2018-04-25       Impact factor: 4.881

10.  Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study.

Authors:  Jingqin Luo; Folasade Agboola; Elizabeth Grant; Colin L Masters; Marilyn S Albert; Sterling C Johnson; Eric M McDade; Jonathan Vöglein; Anne M Fagan; Tammie Benzinger; Parinaz Massoumzadeh; Jason Hassenstab; Randall J Bateman; John C Morris; Richard J Perrin; Jasmeer Chhatwal; Mathias Jucker; Bernardino Ghetti; Carlos Cruchaga; Neill R Graff-Radford; Peter R Schofield; Hiroshi Mori; Chengjie Xiong
Journal:  Neurology       Date:  2020-09-01       Impact factor: 11.800

View more
  1 in total

1.  The iterative process of fluid biomarker development and validation in Alzheimer's disease.

Authors:  Barbara B Bendlin; Henrik Zetterberg
Journal:  Alzheimers Dement (Amst)       Date:  2022-07-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.